Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Systemic Sclerosis
Interventions
RO7303509, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • New York, New York • Dallas, Texas
Conditions
Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions
FLIP topography, Upper Endoscopy
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Redwood City, California
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
Orange, California • Gainesville, Florida • Miami, Florida + 13 more
Conditions
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
Conditions
Morphea, Plaque Form
Interventions
Sarilumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Laser Treatment for the Improvement of Scars and Scleroderma

NCT04567537
Conditions
Scars, Scleroderma
Interventions
Laser Treatment
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions
FT819, Fludarabine, Cyclophosphamide, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
16
States / cities
Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
Conditions
Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
Interventions
UVA-1 Phototherapy, Placebo
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Completed No phase listed Observational Accepts healthy volunteers

Finger Hardness Measure in Scleroderma

NCT01111786
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MTX-474, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
Completed Phase 2 Interventional Results available

Nilotinib in the Treatment of Systemic Sclerosis

NCT01166139
Conditions
Systemic Sclerosis
Interventions
Nilotinib (Tasigna)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Scleroderma, Diffuse
Interventions
AVID200
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
IgPro10, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Scleroderma, Connective Tissue Diseases
Interventions
Oral bovine type I collagen, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 9 more
Conditions
Alveolitis, Systemic Sclerosis
Interventions
Imatinib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
SYSTEMIC SCLERODERMA
Interventions
standard of care, stem cell transplantation
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Chicago, Illinois